SEEK, a London, United Kingdom-based pharmaceutical company, developed the vaccine, called AGS-v. The vaccine is intended to provide broad protection against a range of mosquito-transmitted diseases, as opposed to a specific disease. It is designed to start an immune response to mosquito saliva.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
The clinical trial will enroll up to 60 healthy adults, ages 18 to 50 years. The participants will be randomly assigned to receive one of three vaccine regimens — two injections of the AGS-v vaccine; two injections of AGS-v combined with an adjuvant; or two placebo injections of sterile water.
The study is being conducted at the NIH Clinical Center in Bethesda, Md., and is expected to be completed by summer 2018.
More articles on healthcare quality:
54 hospitals with the best patient discharge communication practices
6 hospitals warning patients of heater-cooler infection risks
CDC revises guidance on controlling C. auris in hospitals
